In vitro study of the immune stimulating activity of an athrophic rhinitis vaccine associated to chitosan microspheres

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 58, Issue 3, 2004, Pages 471-476

  Jiang, Hu Lin ^a   Park, In Kyu ^a   Shin, Na Ri ^a   Kang, Sang Gyun ^a   Yoo, Han Sang ^a   Kim, Su Il ^a   Suh, Sang Bong ^b   Akaike, Toshihiro ^c   Cho, Chong Su ^a  

^a Seoul National University   (South Korea)

^b JAKWANG Co   (South Korea)

^c TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

Bordetella bronchiseptica dermonecrotoxin; Chitosan microspheres; Interferon ; Macrophage; Nasal vaccination; Nitric oxide; Tumor necrosis factor ; Vaccine delivery

Indexed keywords

BACTERIAL TOXIN; BACTERIAL VACCINE; CHITOSAN; MICROSPHERE; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA; VIRULENCE FACTOR;

ALKALINITY; ANIMAL CELL; ARTICLE; ATROPHIC RHINITIS; BACTERIAL VIRULENCE; BORDETELLA BRONCHISEPTICA; CELL LINE; CONTROLLED STUDY; CYTOKINE PRODUCTION; GELATION; IMMUNOSTIMULATION; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PARTICLE SIZE; TIME; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BACTERIAL TOXINS; BACTERIAL VACCINES; BORDETELLA BRONCHISEPTICA; CELL LINE; CHITOSAN; MICE; MICROSPHERES; RHINITIS, ATROPHIC; SWINE; TRANSGLUTAMINASES; VIRULENCE FACTORS, BORDETELLA;

EID: 4644306056     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2004.05.006     Document Type: Article

References (26)

1. Janes K.A., Calvo P., Alonso M.J. Polysaccharide colloidal particles as delivery systems for macromolecules. Adv. Drug Deliv. Rev. 47:2001;83-97
2. Eyles J., Sharp G., Williamson E., Spiers I., Alpar H. Intranasal administration of poly-lactic acid microsphere co-encapsulated Yersinia pestis subunits confers protection from pneumonic plague in the mouse. Vaccine. 16:1998;698-707
3. Mi F.L., Shyu S.S., Chen C.T., Schoung J.Y. Porous chitosan microsphere for controlling the antigen release of Newcastle disease vaccine: preparation of antigen-adsorbed microsphere and in vitro release. Biomaterials. 20:1999;1603-1612
4. Artursson P., Lindmark T., Davis S.S., Illum L. Effect of chitosan on permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm. Res. 11:1994;1358-1361
5. Illum L., Farraj N.F., Davis S.S. Chitosan as a novel nasal delivery system for peptide drugs. Pharm. Res. 11:1994;1186-1189
6. Suzuki K., Ogawa Y., Hashimoto K., Suzuki S., Suzuki M. Protecting e!ect of chitin and chitosan on experimentally induced murine candidasis. Microbiol. Immunol. 28:1984;903-904
7. Saiki I., Murata J., Tokura S., Azuma I. Inhibition by sulfated chitin derivatives of advasion through extracellular matrix and enzymatic degradation metastatic melanoma cells. Cancer Res. 50:1990;3631-3637
8. Lika I., Vine T., Nishimura K., Azuma I. Simulation of non-specific host resistance against Sendai virus and E. coli infection by chitin in mice. Vaccine. 5:1987;270-274
9. Kreuter J., Speiser P.P. New adjutants on poly(methylmethacrylate) base. Infect Immunol. 13:1976;204-210
10. Kreuter J., Speiser P.P. In vitro studies of poly(methylmethacrylate) adjutants. J. Pharm. Sci. 65:1976;1624-1627
11. Kreuter J., Liehl E. Long-term studies of microencapsulated and adsorbed influenza vaccine nanoparticles. J. Pharm. Sci. 70:1981;367-371
12. Kreuter J., Liehl E., Berg V. Influence of hydrophobicity on the adjuvant effect of particlate polymeric adjutants. Vaccine. 6:1988;253-256
13. He P., Davis S., Illum L. In vitro evaluation of the mucoadhesive properties of chitosanmicrospheres. Int. J. Pharm. 166:1998;75-88
14. van der Lubben I.M., Kersten G., Fretz M.M., Beuvery C., Verhoef J.C., Junginger H.E. Chitosan microparticles for mucosal vaccination against diphtheria:oral and nasal efficacy studies in mice. Vaccine. 21:2003;1400-1408
15. Hasebe H. Occurrence and epizootiological surveys of infectious atrophic rhinitis in swine. Nippon Vet. Zootech. Col. Bull. 19:1971;92-102
16. Shin N.R., Choi I.S., Kim J.M., Hur W., Yoo H.S. Effective methods for the production of immunoglobulin Y using immunogens of Brodetella bronchiseptica. Pasteurella multocida and Actinobacillus pleuropneumoniae. J. Vet. Sci. 3:2002;47-57
17. Park I.K., Jiang H.L., Yun C.H., Choi Y.J., Kim S.J., Akaike T., Kim S.I., Cho C.S. Release of Newcastle disease virus from CMsin vitro and in vivo. Asian-Aust. J. Anim. Sci. 17:2004;543-547
18. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., Fukimoto E.K., Geoke N.M., Olson B.J., Klenk D.C. Measurement of protein using bicinchoninic acid. Anal. Biochem. 150:1985;76-85
19. Xu Y.M., Du Y. Effect of molecular structure of chitosan on protein delivery properties of chitosan nanoparticles. Int. J. Pharm. 250:2003;215-226
20. 15N] nitrate in biological fluids. Anal. Biochem. 126:1992;131-138
21. Eldridge J.H., Hammond C.J., Meulbrock J.A., Staas J.K., Gilley R.M., Rice T.R. Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the peyer's patches. J. Control. Release. 11:1990;205-214
22. Lydyard P., Grossi C. The lymphoid system. Immunology. 5:1998;31-42
23. Bowersock T.L., Martin S. Vaccine delivery to animals. Adv. Drug Deliv. Rev. 38:1999;167-194
24. Lorenzo-Lamosa M.L., Remuñán-López C., Vila-Jato J.L., Alonso M.J. Design of microencapsulated chitosan microspheres for colonic drug delivery. J. Control. Release. 52:1998;109-118
25. Jeong H.J., Koo H.N., Oh E.Y., Chae H.J., Kim H.R., Suh S.B., Kim C.H., Cho K.H., Park B.R., Park S.T. Nitric oxide production by high molecular weight water-soluble chitosan via nuclear factor-κB activation. Int. J. Immunopharm. 22:2000;923-933
26. Jabbal-Gill I., Fisher A.N., Rappuoli R., Davis S.S., Illum L. Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice. Vaccine. 16:1998;2039-2046